<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112740">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02055066</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-111-1301</org_study_id>
    <nct_id>NCT02055066</nct_id>
  </id_info>
  <brief_title>A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.</brief_title>
  <official_title>A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>arGEN-X  BVBA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>arGEN-X  BVBA</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a first-in-human study of an antibody blocking the function of the oncogene c-met in
      patients with cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1b trial will characterize the safety profile of ARGX 111 and will thus provide
      the first elements towards establishing an accurate risk-benefit assessment for ARGX 111 in
      cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with grade 3 or 4 toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profiles (Cmax , Ctrough, AUC, Vd  , clearance, and half-life)</measure>
    <time_frame>C1 D1 (pre, 0h, 2h, 6h, 12h, 24h), C1D8, C1D15; Cycle ≥2  o D1 pre-/post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measurement of drug concentration in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (Hepatocyte growth factor; ADCC)</measure>
    <time_frame>Base-line and pre-dose at each cycle for an average of 4 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>measurements of cytokine changes in blood as a result of drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events per dose level</measure>
    <time_frame>for an average of 4 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARGX-111 0.3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARGX-111 1.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARGX-111 3.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARGX-111 10 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARGX-111</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent.

          2. Age ≥ 18 years.

          3. Performance status of 0 or 1.

          4. Histological diagnosis of malignancy.

          5. Cancer relapsing after, or refractory to standard therapy.

          6. Malignancy over-expressing the c Met protein.

          7. Presence of circulating tumor cells (CTCs).

          8. At least one tumor lesion &gt; 2 cm on PET/CT.

          9. Serum albumin &gt; 35 g/L.

         10. Absolute neutrophil count (ANC) &gt; 1.0 x 109/L.

         11. Hemoglobin &gt; 90 g/L (0.9 g/dL).

         12. Platelet count ≥ 75 x 109/L.

         13. Coagulation parameters ≤ 1.5 x ULN.

         14. Total bilirubin ≤ 1.5 x upper limit of normal (ULN).

         15. Creatine Phosphokinase (CPK) ≤ 2.5 x ULN.

         16. Serum creatinine ≤ 1.5 x ULN.

         17. Ability to comply with protocol-specified procedures/evaluations and scheduled
             visits.

        Exclusion Criteria:

          1. History or clinical evidence of neoplastic central nervous system (CNS) involvement.

          2. Major surgery within 4 weeks of ARGX 111 first dose administration.

          3. Systemic glucocorticoid administration at doses greater than physiological
             replacement (prednisone 20 mg equivalent) within 3 weeks of ARGX 111 first dose
             administration.

          4. Cytotoxic chemotherapy within 3 weeks of ARGX 111 first dose administration.

          5. Radiation therapy with curative intent within 3 weeks of ARGX 111 first dose
             administration.

          6. Biological therapy (monoclonal antibodies) within 4 weeks of ARGX 111 first dose
             administration.

          7. Biological therapy (other than monoclonal antibodies) within 5 half-lives of ARGX 111
             first dose administration.

          8. Unresolved Grade 3 or 4 toxicity from prior therapy, including experimental therapy.

          9. History of recurrent Grade 3 or 4 toxicity from anti c Met therapy.

         10. Uncontrolled diabetes, defined as fasting glycemia &gt; 150 mg/dl).

         11. Active, untreated viral, bacterial, or systemic fungal infection.

         12. Any clinical finding, including psychiatric and behavioral problems, which, in the
             opinion of the Investigator, precludes the patient from safely participating in the
             study.

         13. Childbearing potential (unless using an adequate measure of contraception).

         14. Pregnancy or lactation.

         15. History of severe (Grade 3 or 4) hypersensitivity to recombinant proteins.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitair Zieckenhuis Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Rolfo, MD</last_name>
      <email>christian.rolfo@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Aftimos, MD</last_name>
      <email>philippe.aftimos@jbi.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>January 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>c-MET</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
